UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 9, 2023

Seer, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-39747 (Commission File Number)

3800 Bridge Parkway, Suite 102 Redwood City, California 94065 (Address of principal executive offices, including zip code)

650-453-0000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Common Stock, par value \$0.00001 per share	SEER	The NASDAQ Stock Market LLC (The NASDAQ Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

82-1153150 (I.R.S. Employer Identification No.)

Item 2.02 – Results of Operations and Financial Condition.

On May 9, 2023, Seer, Inc. (the "Company") issued a press release (the "Press Release") announcing results for the quarter ended March 31, 2023. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01 Financial Statements and Exhibits

Exhibit No.

Description

<u>99.1</u> Press Release, dated May 9, 2023
104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEER, INC.

Date: May 9, 2023

By: /s/ David Horn

David Horn Chief Financial Officer

Seer Reports First Quarter 2023 Financial Results

Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications

REDWOOD CITY, Calif. May 9, 2023 – Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first guarter ended March 31, 2023.

"We started the year off strong with continued growth in our installed base and progress against our strategic objectives. It is exciting to see the Proteograph enable breakthrough science, with increasing data demonstrating its power, extensibility, and catalyzation of new applications," said Omid Farokhzad, CEO and President. "We are seeing more data being generated by our customers, the initiation of larger studies, and the first customer publications make their way through the peer-review process. We expect this momentum to continue throughout the year as more customers adopt the technology and scale their use of the platform."

Recent Highlights

- · Achieved revenue of \$4.1 million for the first quarter of 2023, an increase of 22% over the prior year period
- Announced the first protein quantitative trait loci, or pQTL, customer manuscript, demonstrating the association of genetic variants with
 protein variants at peptide-level resolution in healthy and diabetic patients, now available as a pre-print on *BioRxiv*
- Announced a peer-reviewed article published in PLOS ONE, which shows the advantage of multiple peptide measurements per protein over single protein measurements, using them to identify examples of previously unknown differential protein isoform abundance in lung cancer vs. healthy controls
- Presented ten posters at the US Human Proteome Organization conference highlighting the Proteograph Product Suite, including customer data on COVID-19 vaccine response and a robust, high-throughput method for deep plasma proteomics

First Quarter 2023 Financial Results

Revenue was \$4.1 million for the three months ended March 31, 2023, a 22% increase from \$3.3 million for the three months ended March 31, 2022. The increase was primarily due to increased sales of consumable kits related to the Proteograph Product Suite. Product-related revenue for the first quarter of 2023 was \$3.6 million, including \$1.3 million of related party revenue, and consisted of sales of SP100 instruments, consumable kits and platform evaluations. Service revenue was \$0.1 million and grant and other revenue was \$0.3 million.

Gross profit, inclusive of grant and other revenue, was \$2.1 million and gross margin was 51% for the first quarter of 2023.

Operating expenses were \$29.5 million for the first quarter of 2023, including \$8.7 million of stock-based compensation, an increase of 18%, as compared to \$25.0 million, including \$8.1 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other

related expenses, including stock-based compensation, product development efforts related to the Proteograph Product Suite, and expenses associated with build-out of expansion facilities.

Net loss was \$24.0 million for the first quarter of 2023, as compared to \$23.6 million for the corresponding prior year period.

Cash, cash equivalents and investments were \$410.5 million as of March 31, 2023.

2023 Guidance

Seer continues to expect full year 2023 revenue to be in the range of \$23 million to \$25 million, representing growth of 48% - 61% over full year 2022.

Webcast Information

Seer will host a conference call to discuss the first quarter 2023 financial results on Tuesday, May 9, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer

Seer[™] is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph[™] Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit <u>www.seer.bio</u>.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company's current views with respect to certain current and future events and financial performance. Words such as "expects," "anticipates," "projects," "intends," "plans," "believes," "estimates," variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company's outlook for fiscal year 2023. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Quarterly Report on Form 10-Q, to be filed with the SEC, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact: Carrie Mendivil investor@seer.bio

<u>Media Contact:</u> Karen Possemato

pr@seer.bio

Seer, Inc. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts)

	Three Months Ended March 31,	
	2023	2022
Revenue:		
Product	\$ 2,343	\$ 2,149
Service	69	79
Related party	1,306	1,070
Grant and other	335	14
Total revenue	4,053	3,312
Cost of revenue:		
Product	1,436	1,660
Service	7	14
Related party	478	394
Grant and other	64	
Total cost of revenue	1,985	2,068
Gross profit	2,068	1,244
Operating expenses:		
Research and development	14,474	10,732
Selling, general and administrative	15,039	14,298
Total operating expenses	29,513	25,030
Loss from operations	(27,445)	(23,786)
Other income (expense):		
Interest income	3,717	144
Other expense	(231)	(4)
Total other income	3,486	140
Net loss	\$ (23,959)	\$ (23,646)
Other comprehensive loss:		
Unrealized gain (loss) on available-for-sale securities	1,158	(1,691)
Comprehensive loss	\$ (22,801)	\$ (25,337)
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.38)	\$ (0.38)
Weighted-average common shares outstanding, basic and diluted	63,543,094	62,003,504

Seer, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts)

Short-term investments 303,708 304,703 304 304,723,75 404 400 304,73,75 404 406 406,75 833 303,708 303,708 303,708 303,708 303,708 304 304 305,73,75 404 406 406,75 Restricted cash 533 303,708 303,708 303,708 303,708 303,708 303,708 303,708 303,708 303,708 303,708 303,708 304,775 404 406 406,75 804,75,75 404,75,75 404,775		March 31, 2023	December 31, 2022
Current assets: 5 48,366 \$ Cash and cash equivalents 303,708 \$ \$ Short-term investments 303,708 \$ \$ Accounts receivable, net 4.735 \$ \$ Related party receivables 1.303 \$ \$ Other receivables 1.065 \$ \$ Inventory 3.718 \$ \$ Prepaid expenses and other current assets 4.380 \$ \$ Cong-term investments \$ \$ \$ \$ Operating lease right-of-use assets 26.944 \$		(unaudited)	
Cash and cash equivalents \$ 48,386 \$ Short-term investments 303,708 : Related party receivable, net 4,725 . Related party receivables 1,383 . Other receivables 1,665 . Inventory 3,718 . Preprid expenses and other current assets 4,300 . Construction investments 56,4416 . Operating lease right-of-use assets 26,544 . Property and equipment, net 18,675 . Restricted cash . . . Other assets Current liabilities: Accounts payable \$ 1.956 \$ Other current liabilities: . <td>ASSETS</td> <td></td> <td></td>	ASSETS		
Short-term investments 303,708 3 Accounts receivable, net 4,735 4,735 Related party receivables 1,065 1 Other receivables 1,065 1 Inventory 3,718 3 Prepaid expenses and other current assets 367,375 0 Total current assets 367,375 0 Property and equipment, net 18,675 0 Restricted cash 524 0 Other assets 953 0 Total assets \$ 472,787 \$ 4 Current liabilities: \$ 1,956 \$ Accounts payable \$ 1,956 \$ Accounts payable \$ 1,956 \$ Operating lease liabilities, current 2,188 0 Other ranent liabilities 172 172 Total current liabilities 360 174 Operating lease liabilities, current 2,188 300 Other current liabilities 360 175 Operating lease liabilitities, current option 27,684	Current assets:		
Accounts receivable, net 4,735 Related party receivables 1,383 Other receivables 1,065 Inventory 3,718 Prepaid expenses and other current assets 4,380 Total current assets 367,375 Long-term investments 58,416 Operating lease right-of-use assets 26,944 Property and equipment, net 18,675 Restricted cash 54 Other assets 58 Total assets 5 Total assets 5 Cartent liabilities: 5 Accounts payable 5 Accounts payable 5 Other current liabilities, current 2,188 Other current liabilities, current 2,188 Other current liabilities 11,754 Operating lease liabilities, net of current portion 27,684 Other norument liabilities 39,798 Commitments and contingencies 39,798 Stockholders' equity: - Preferred stock, \$0,00001 par value; \$,000,000 shares authorized as of March 31, 2023 and December 31, 2023 and December 31, 2022, expectively 1 Class A comm	Cash and cash equivalents	\$ 48,386	\$ 53,208
Related party receivables 1,383 Other receivables 1,065 Inventory 3,718 Preprid expenses and other current assets 367,375 Cangeterm investments 367,375 Compariting lease right-of-use assets 367,375 Properiy and equipment, net 18,675 Restricted cash 524 Other assets 833 Total assets 5472,787 Carnert liabilities: 843 Accounts payable 51,956 Account spayable 51,956 Other current liabilities 11,754 Other current liabilities 11,754 Operating lease liabilities, current 2,188 Other current liabilities 360 Total asset 360 Total liabilities 360 Total liabilities 360 Total liabilities 360 Total liabilities 360 Total current liabilities 360 Total current liabilities 360 Total liabilities 360 Total li	Short-term investments	303,708	368,031
Other reveales 1,065 Inventory 3,718 Prepaid expenses and other current assets 4,380 Total current assets 367,375 Long-term investments 58,416 Operating lease right-of-use assets 26,944 Property and equipment, net 18,675 Restricted Cash 524 Other assets 853 Total assets 853 Current liabilities: 4,27,877 Accounts payable \$ 1,956 Accounts payable \$ 1,956 Other rowenue 263 Other current liabilities, current 2,188 Other current liabilities 11,754 Operating lease liabilities, net of current portion 27,684 Other current liabilities 39,99 Commitments and contingencies 360 Stockholders' equity: - Prefered toxel, \$00,0001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022, and December 31, 2023, and December 31, 2022, and December 31, 2022, and December 31, 2023, and December 31, 2022, and December 31, 2022, and December 31, 2022, and De	Accounts receivable, net	4,735	4,315
Inventory 3,718 Prepaid expenses and other current assets 4,380 Total current assets 367,375 Long-term investments 367,375 Operating lesse right-of-use assets 26,944 Property and equipment, net 18,675 Restricted cash 524 Other assets 8436 Total assets 54 472,787 Total assets 54 722,787 Current liabilities: 42,2787 Accounts payable \$ 1,956 Accounts payable \$ 1,956 Operating lesse liabilities, current 2,188 Other current liabilities 11,754 Operating lesse liabilities, net of current portion 27,684 Other noncurrent liabilities 39,798 Commitments and contingencies 39,798 Stockholders' equity: - Preferred stock, \$0,00001 par value; \$,000,000 shares authorized as of March 31, 2023 and December 31, 2023 and December 31, 2022, respectively - Class A common stock, \$0,00001 par value; \$,000,000 shares authorized as of March 31, 2023 and December 31, 2023 and December 31, 2022, respectively - Class A common	Related party receivables	1,383	1,804
Prepaid expenses and other current assets 4,380 Total current assets 367,375 Long-term investments 58,416 Operating lease right-of-use assets 26,944 Property and equipment, net 18,675 Restricted cash 524 Other assets 633 Total assets 633 Current liabilities: 8472,787 Accounts payable \$ 1,956 Accounts payable \$ 1,956 Operating lease liabilities, current 2,188 Other current liabilities 11,754 Operating lease liabilities, net of current portion 27,684 Other current liabilities 300 Total laibilities 39,798 Commitments and contingencies 39,798 Stockholders' equity: - Preferred toxel, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022 - Class A common stock, \$0,00001 par value; 94,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively - Class B common stock, \$0,00001 par value; 94,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively -	Other receivables	1,065	899
Total current assets367,375Long-term investments58,416Operating lease right-of-use assets26,944Property and equipment, net18,675Restricted cash524Other assets853Total assets\$ 472,787Current liabilities:\$ 472,787Accounts payable\$ 1,956Accounts payable\$ 1,956Accounts payable\$ 1,956Other current liabilities;7,175Deferred revenue263Operating lease liabilities, current2,188Other current liabilities11,754Operating lease liabilities, not of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingencies3000001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, S00,0001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, S0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, S0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, S0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, S0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, S0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 a	Inventory	3,718	4,627
Long-term investments 58,416 Operating lease right-of-use assets 26,944 Property and equipment, net 18,675 Restricted cash 524 Other assets 853 Total assets 853 Current liabilities: \$ 472,787 Accounts payable \$ 1,956 Accounts payable \$ 1,956 Accounts payable 263 Operating lease liabilities; current 2,188 Other current liabilities 11,754 Operating lease liabilities, net of current portion 27,684 Other noncurrent liabilities 360 Total labilities 360 Total liabilities 39,798 Comminments and contingencies 5 Stockholders' equity: - Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022, and December 31, 2022, respectively - Class A common stock, \$0.00001 par v	Prepaid expenses and other current assets	4,380	2,098
Operating lease right-of-use assets 26,944 Property and equipment, net 18,675 Restricted cash 524 Other assets 853 Total assets 853 LABBLITIES AND STOCKHOLDERS' EQUITY 5 Current liabilities: 7,175 Accounts payable \$ 1,956 Accounts payable 7,175 Deferred revenue 2,188 Other current liabilities, current 2,188 Other current liabilities, current 2,188 Other current liabilities, net of current portion 27,684 Other noncurrent liabilities, net of current portion 27,684 Total liabilities 360 Commitments and contingencies 39,798 Stockholders' equity: 7 Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022, resp shares issued and outstanding as of March 31, 2023 and December 31, 2022, and December 31, 2022, resp Store size authorized as of March 31, 2023 and December 31, 2022, resp Store size authorized as of March 31, 2023 and December 31, 2022, resp Store size authorized as of March 31, 2023 and December 31, 2022, resp Store size authorized as of March 31, 2023 and December 31, 2022, resp Store size size autho dustanding as of March 31, 2023 and December 31, 2	Total current assets	367,375	434,982
Property and equipment, net 18,675 Restricted cash 524 Other assets 853 Total assets \$ 472,787 \$ 4 LIABILITIES AND STOCKHOLDERS' EQUITY ************************************	Long-term investments	58,416	5,157
Restricted cash 524 Other assets 525 Total assets 524 Chreme tabilities: Accound spashle 51,956 Accound expenses 7,175 Deferred revenue 263 Operating lease liabilities, current 2,188 Other current liabilities 1172 Total current liabilities 1172 Total current liabilities 1172 Operating lease liabilities, current 02,188 Other current liabilities 311,754 Operating lease liabilities, and concurrent portion 27,684 Other noncurrent liabilities 360 Total liabilities 360 Total liabilities 360 Commitments and contingencies Stockholders' equity: Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; Class A common stock, \$0,00001 par value; 9,4000,000 shares authorized as of March 31, 2023 and December 31, 2023 and December 31, 2022; Class A common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2023 and December 31, 2022; Class A common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2023, respectively 1 Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2023, respectively Additional paid-in capital 676,536 (03) Accumulated other comprehensive loss (93)	Operating lease right-of-use assets	26,944	27,003
Other assets 853 Total assets \$ 472,787 \$ 472,787 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 1,956 \$ Operating lease liabilities, current \$ 1,85 Other current liabilities 11754 \$ Operating lease liabilities, net of current portion \$ 7,684 Other noncurrent liabilities 360 \$ Total liabilities 39,798 \$ Commitments and contingencies \$ \$ Stockholders' equity: \$ \$ \$ Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; and December 31, 2022; so,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; and A,044,9499 shares is	Property and equipment, net	18,675	19,408
Total assets\$ 472,787\$ 4LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable\$ 1,956\$Accounts payable\$ 1,956\$Accrued expenses7,175Deferred revenue263Operating lease liabilities, current2,188Other current liabilities11754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingenciesStockholders' equity:Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022	Restricted cash	524	524
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 1,956 Accounts payable \$ 263 Operating lease liabilities, current \$ 2,188 Other current liabilities 172 Total current liabilities 11,754 Operating lease liabilities, net of current portion 27,684 Other noncurrent liabilities 360 Total liabilities 39,798 Commitments and contingencies 39,798 Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022, zero shares issued and outstanding as of March 31, 2023 and December 31, 2023, respectively	Other assets	853	855
Current liabilities:Accounts payable\$ 1,956Accrued expenses7,175Deferred revenue263Operating lease liabilities, current2,188Other current liabilities11,22Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingencies39Stockholders' equity:7Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 259,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively1Class A common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0,000001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class A common stock, \$0,000001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0,000001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively	Total assets	\$ 472,787	\$ 487,929
Accounts payable\$ 1,956\$Accrued expenses7,175Deferred revenue263Operating lease liabilities, current2,188Other current liabilities172Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingencies39,798Stockholders' equity:9Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; s9,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; nespectively1Additional paid-in capital676,5360Accumulated other comprehensive loss(93)Accumulated deficit(243,455)(2	LIABILITIES AND STOCKHOLDERS' EQUITY		
Accrued expenses7,175Deferred revenue263Operating lease liabilities, current2,188Other current liabilities172Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities360Commitments and contingencies39,798Stockholders' equity:2Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; spectively1Class A common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; spectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; spectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; spectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; spectively1Class A common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively2Additional paid-in capital676,5360Accumulated other comprehensive loss(93)Accumulated deficit(243,455)(2	Current liabilities:		
Deferred revenue263Operating lease liabilities, current2,188Other current liabilities172Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities360Total liabilities39,798Commitments and contingencies500Stockholders' equity:500,0000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0,00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively6Additional paid-in capital676,5360Accumulated other comprehensive loss(93)Accumulated deficit(243,455)(2	Accounts payable	\$ 1,956	\$ 2,104
Operating lease liabilities, current2,188Other current liabilities172Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingencies360Stockholders' equity:7Preferred stock, \$0,00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; sero shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; 4,044,969 and 4,044,969 shares issued and outstanding as of March 31, 2023 and December 31, 2022; 4,044,969 and 4,044,969 shares issued and outstanding as of March 31, 2023 and December 31, 2022; erepectively	Accrued expenses	7,175	8,298
Other current liabilities172Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities360Commitments and contingencies39,798Stockholders' equity:	Deferred revenue	263	133
Total current liabilities11,754Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingencies39,798Stockholders' equity:2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; sense shares issued and sp,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; sense shares issued and outstanding as of March 31, 2023 and December 31, 2022; sense shares issued and outstanding as of March 31, 2023 and December 31, 2022; sense shares issued and outstanding as of March 31, 2023 and December 31, 2022; sense shares issued and outstanding as of March 31, 2023 and December 31, 2022; sense shares issued and outstanding as of March 31, 2023 and December 31, 2022; sensectively1Class A common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively	Operating lease liabilities, current	2,188	1,842
Operating lease liabilities, net of current portion27,684Other noncurrent liabilities360Total liabilities39,798Commitments and contingencies9Stockholders' equity:9Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively	Other current liabilities	172	207
Other noncurrent liabilities360Other noncurrent liabilities39,798Commitments and contingencies39,798Commitments and contingencies5tockholders' equity:Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; sero shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; sepectively	Total current liabilities	11,754	12,584
Total liabilities39,798Commitments and contingenciesStockholders' equity:Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; s9,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively1Class A common stock, \$0.00001 par value; 9,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively	Operating lease liabilities, net of current portion	27,684	28,032
Commitments and contingenciesStockholders' equity:Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022Class A common stock, \$0.00001 par value; 94,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectivelyClass A common stock, \$0.0001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.0001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.0001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.0001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.0001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.0001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively1Additional paid-in capitalAdditional paid-in capitalAccumulated other comprehensive loss(243,455)(2222233344444444444444	Other noncurrent liabilities	360	320
Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; so,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively	Total liabilities	39,798	40,936
Stockholders' equity: Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; so,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; so,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 1 Class A common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively 1 Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively 1 Class I common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; respectively	Commitments and contingencies		
Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022; sero shares issued and outstanding as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022; respectively	-		
December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively1Class B common stock, \$0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 4,044,969 and 4,044,969 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively—Additional paid-in capital676,536(93)Accumulated other comprehensive loss(93)Accumulated deficit(243,455)(2	Preferred stock, \$0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31,	_	_
December 31, 2022; 4,044,969 and 4,044,969 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively—Additional paid-in capital676,536(93)Accumulated other comprehensive loss(93)(243,455)(243,455)	December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023	1	1
Accumulated other comprehensive loss (93) Accumulated deficit (243,455)	December 31, 2022; 4,044,969 and 4,044,969 shares issued and outstanding as of March 31, 2023 and	_	_
Accumulated deficit (243,455) (2	Additional paid-in capital	676,536	667,739
		(93)	(1,251)
	Accumulated deficit	(243,455)	(219,496)
1 5	Total stockholders' equity		446,993
Total liabilities and stockholders' equity \$ 472,787 \$ 472,787			· · · ·